Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TScan Therapeutics (TCRX) Equity Ratio (2020 - 2025)

Historic Equity Ratio for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to 0.55.

  • TScan Therapeutics' Equity Ratio fell 1656.19% to 0.55 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.55, marking a year-over-year decrease of 1656.19%. This contributed to the annual value of 0.65 for FY2024, which is 1712.87% up from last year.
  • Latest data reveals that TScan Therapeutics reported Equity Ratio of 0.55 as of Q3 2025, which was down 1656.19% from 0.59 recorded in Q2 2025.
  • TScan Therapeutics' 5-year Equity Ratio high stood at 0.87 for Q1 2022, and its period low was 0.46 during Q2 2021.
  • Moreover, its 5-year median value for Equity Ratio was 0.62 (2023), whereas its average is 0.59.
  • Per our database at Business Quant, TScan Therapeutics' Equity Ratio soared by 28706.74% in 2022 and then crashed by 4810.84% in 2023.
  • Over the past 5 years, TScan Therapeutics' Equity Ratio (Quarter) stood at 0.85 in 2021, then tumbled by 41.57% to 0.5 in 2022, then rose by 11.0% to 0.55 in 2023, then grew by 17.13% to 0.65 in 2024, then decreased by 15.41% to 0.55 in 2025.
  • Its Equity Ratio was 0.55 in Q3 2025, compared to 0.59 in Q2 2025 and 0.63 in Q1 2025.